Amantadine therapy for chronic hepatitis C: a dose escalation study

Smith JP; Riley 3rd; Bingaman S; Mauger DT; Shahram Mirmomen

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue Accepted Manuscripts All Issues In Press Articles Search

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Amantadine therapy for chronic hepatitis C: a dose escalation study

Author(s):

Smith JP¹,

Riley TR 3rd¹,

Bingaman S¹,

Mauger DT¹,

Shahram Mirmomen^2,*

2Gastroenterologist ,Tehran University of MedicalSciences,lmam KhomeiniHospital, [email protected], Tehran, IR.Iran

Hepatitis Monthly:Vol. 4, issue 7; 83-84

Published online:Sep 30, 2004

Article type:Letter

How to Cite:JP S, 3rd R, S B, DT M, Mirmomen S. Amantadine therapy for chronic hepatitis C: a dose escalation study. Hepat Mon. 2004;4(7):. doi:

Abstract

OBJECTIVES: Amantadine reduces liver transaminase levels in some patients with chronic hepatitis C at doses of 200 mg daily and may improve the sustained virological response (SVR) when given with interferon and ribavirin. The primary purpose of the present investigation was to study the safety and toxicity of higher doses of amantadine in subjects who previously failed or were intolerant to interferon. The secondary aim was to test the efficacy of higher dose of amantadine against hepatitis C.

METIIODS: An open-labeled prospective study was conducted starting with amantadine 200 mg daily and increasing to 500 mg daily while monitoring for safety, tox icity, and efficacy. An amantad ine blood level exceeding 1,600 ng/ml was considered toxic requiring dose reduction. The patient's symptoms, laboratory tests, and quality of life were monitored .

RESULTS: One hundred patients enrolled in th e s tud y. Normalization of alanine aminotransferase (ALT) for each dose was as follows: 200 mg (35%), 300 mg (49%), 400 mg (53%), and 500 mg (56%). The incidence of toxic amantadine plasma levels increased with dose, i.e ., 200 mg (0%), 300 mg (6%),400 mg (27%), and 500 mg (49%). The frequency and severity of arthralgia and fatigue improved at all dosages administered. No changes in the occurrence or severity of headache, insomnia, or depression were reported. Serious adverse events included myocardial infarction and suicide attempt. Other side effects in cluded impotence, confusion, alopec ia, and hoarseness.

CONCLUSIONS: Amantadine given at a dose of300 mg daily is safe, and sign ificantly lowers AL T blood levels more than 200 mg daily. The enzyme response rate does not significantly improve above 300 mg, but toxicity increases.

Keywords

Article

Full Text

Full text is available in PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 1 week ago
Scopus by Title: 20
Last Update: 1 week ago
Scopus by Title (Ref): 0
Last Update: 1 week ago
CrossRef: 0
Last Update: 2 days ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Smith JP:[PubMed][Scholar]
Riley 3rd:[PubMed][Scholar]
Bingaman S:[PubMed][Scholar]
Mauger DT:[PubMed][Scholar]
Shahram Mirmomen:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

Amantadine therapy for chronic hepatitis C: a dose escalation study

Abstract

Full Text

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 2 days ago